Earnings Scheduled For March 24, 2022
Companies Reporting Before The Bell
• iHuman (NYSE:IH) is likely to report earnings for its fourth quarter.
The Week Ahead In Biotech (March 6-12): Quiet Week On Tap With Earnings Season Reaching It Final Leg
Biotech stocks reversed course in the week ending March 4, as the Ukrainian crisis weighed down on the broader market as well as the sector. The iShares Biotechnology ETF (NASDAQ: IBB) retreated in four out of five sessions of the week.
FDA Slaps Clinical Hold On Celyad’s Phase 1 Colorectal Cancer Trial
The FDA has issued a clinical hold on Celyad Oncology SA’s (NASDAQ:CYAD) CYAD-101-002 (KEYNOTE-B79) Phase 1b trial due to insufficient information to…
Celyad Oncology Announced FDA Clinical Hold of CYAD-101-002 Phase 1b Trial
Celyad Oncology SA (Brussels:CYAD) (Paris:CYAD) (NASDAQ: CYAD) (Euronext & Nasdaq: CYAD) (the "Company"), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced that on March 1, 2022, the Company was informed via e-mail c
Stocks That Hit 52-Week Lows On Tuesday
During Tuesday's trading, 98 companies set new 52-week lows.
Wells Fargo Maintains Overweight on Celyad Oncology, Lowers Price Target to $11
Wells Fargo analyst John Abbott maintains Celyad Oncology (NASDAQ:CYAD) with a Overweight and lowers the price target from $20 to $11.
Celyad Oncology Early Monday Highlighted Presentation Of Updates On Its Short Hairpin RNA-Based CAR T Programs At American Society Of Hematology Meeting: ‘Data continues to support the versatile potential of non-gene edited shRNA technology with update…
Data continues to support the versatile potential of non-gene edited shRNA technology with updates from the CYAD-02 and CYAD-211 clinical programs
Management to host conference call today December 13th at 2:30 p.m.